BRCA突变结直肠癌的临床病理特征与预后分析
研究检测132例结直肠癌手术标本的BRCA突变,分析其与临床病理特征、免疫细胞浸润及预后的关系。BRCA总突变率9.09%,突变组肿瘤较小、侵袭性较低、T细胞浸润密度更高且TMB-H比例更高,但总生存无差异。临床分期是总生存的独立影响因素。
要点
- 结直肠癌BRCA总突变率9.09%,以BRCA2突变为主(6.06%)。
- BRCA突变组肿瘤更小、脉管神经侵犯更少、肿瘤出芽级别更低。
- BRCA突变组CD3+、CD4+、CD8+ T细胞浸润密度均显著高于野生型。
核心结论
- BRCA突变的结直肠癌侵袭性较低、TMB-H比例更高且肿瘤微环境免疫细胞浸润丰富,提示更可能从免疫治疗中获益。
- BRCA突变状态与结直肠癌患者总生存无关,临床分期是总生存的独立影响因素。
研究设计与样本
- 回顾性收集2018—2021年山西省肿瘤医院手术切除的结直肠癌组织标本132例。
- 采用二代测序检测BRCA突变,免疫组化检测CD3+、CD4+、CD8+ T细胞和CD20+ B细胞浸润密度。
- 分析BRCA突变与临床病理特征、免疫浸润及预后的关系。
主要发现
- BRCA总突变率9.09%(12/132),BRCA1突变率3.03%(4/132),BRCA2突变率6.06%(8/132)。
- BRCA突变组肿瘤较小(P=0.036),脉管或神经侵犯较少(P=0.041),肿瘤出芽级别偏低(P=0.013)。
- BRCA突变组CD4+ T细胞浸润密度为438.36(97.37, 718.43)个/mm²,高于野生型组89.34(58.15, 178.35)个/mm²(P<0.05)。
临床怎么用
- 对结直肠癌患者可考虑检测BRCA突变以识别免疫治疗潜在获益人群。
- BRCA突变结直肠癌患者仍需按临床分期进行预后评估和分层管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the mutation status of breast cancer susceptibility genes (BRCA) in colorectal cancer and the relationship between BRCA and the clinical-pathological characteristics and prognosis of colorectal cancer. Methods: A total of 132 colorectal cancer tissue specimens surgically resected at Shanxi Cancer Hospital from 2018 to 2021 were collected. Second-generation sequencing was used to detect BRCA mutations. Immunohistochemical staining assessed the infiltration density of CD3+, CD4+, and CD8+ T cells, and CD20+ B cells. The association between BRCA mutations and clinical-pathological features, immune cell infiltration density, and prognosis of colorectal cancer was analyzed. Results: Among 132 colorectal cancer cases, the overall BRCA mutation rate was 9.09% (12/132), with BRCA1 mutation rate at 3.03% (4/132) and BRCA2 mutation rate at 6.06% (8/132). Compared with the BRCA wild-type group, the BRCA mutation group exhibited smaller tumors (P=0.036), less vascular or nerve invasion (P=0.041), and lower tumor budding grades (P=0.013). Tumor microenvironment analysis revealed that the infiltration densities of CD3+, CD4+, and CD8+ T cells in the BRCA mutation group were 1 729.66 (652.91, 3 065.98)/mm², 438.36 (97.37, 718.43)/mm², and 1 017.86 (506.19, 2 257.35)/mm², respectively, all higher than those in the BRCA wild-type group [555.72 (304.58, 933.26)/mm², 89.34 (58.15, 178.35)/mm², and 354.23 (157.78, 752.37)/mm², respectively, all P<0.05]. Molecular feature analysis revealed five cases of TMB-H in the BRCA-mutant group and three cases in the BRCA-wild group, with a statistically significant difference between the two groups (P<0.001). Survival analysis revealed no association between BRCA mutation status and overall survival in colorectal cancer patients (P>0.05). Multivariate Cox regression analysis identified clinical stage as an independent predictor of overall survival, with patients at stages Ⅲ-Ⅳ exhibiting poorer prognosis (HR=5.359, 95% CI: 1.124-25.546). Conclusion: BRCA-mutated colorectal tumors exhibit lower invasiveness, higher TMB-H rates, and abundant immune cell infiltration in the tumor microenvironment, suggesting that patients with BRCA-mutated colorectal cancer are more likely to benefit from immunotherapy. 目的: 探讨乳腺癌易感基因(BRCA)在结直肠癌中的突变情况,及BRCA与结直肠癌临床病理特征和预后的关系。 方法: 收集2018—2021年在山西省肿瘤医院手术切除的结直肠癌组织标本132例,采用二代测序技术检测BRCA突变,采用免疫组化染色方法检测CD3+ T细胞、CD4+ T细胞、CD8+ T细胞和CD20+ B细胞的浸润密度,分析BRCA突变与结直肠癌临床病理特征、免疫细胞浸润密度及预后的关系。 结果: 132例结直肠癌中,BRCA基因总突变率为9.09%(12/132),其中BRCA1突变率为3.03%(4/132),BRCA2突变率为6.06%(8/132)。与BRCA野生组比较,BRCA突变组的肿瘤较小(P=0.036),脉管或神经侵犯较少(P=0.041),肿瘤出芽级别偏低(P=0.013)。肿瘤微环境分析显示,BRCA突变组CD3+ T细胞、CD4+ T细胞及CD8+ T细胞浸润密度分别为1 729.66(652.91,3 065.98)、438.36(97.37,718.43)和1 017.86(506.19,2 257.35)个/mm²,均高于BRCA野生型组[分别为555.72(304.58,933.26)、89.34(58.15,178.35)和354.23(157.78,752.37)个/mm²,均P<0.05]。分子特征分析显示,BRCA突变组TMB-H有5例,BRCA野生组有3例,两组差异有统计学意义(P<0.001)。生存分析显示,BRCA突变与结直肠癌患者的总生存时间无关(P>0.05)。多因素Cox回归分析显示,临床分期是结直肠癌患者总生存时间的独立影响因素,Ⅲ~Ⅳ期患者预后较差(HR=5.359,95% CI:1.124~25.546)。 结论: BRCA突变的结直肠癌肿瘤侵袭性较低、TMB-H比例更高,且肿瘤微环境中存在丰富的免疫细胞浸润,提示BRCA突变结直肠癌患者更有可能从免疫治疗中获益。.
引用
- Liu J, Zhang X, Lu HX, et al. [Clinical and pathological characteristics and prognostic analysis of colorectal cancer associated with breast cancer susceptibility gene mutations]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 41688208. doi:10.3760/cma.j.cn112152-20250828-00424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。